Literature DB >> 1976394

Mutational activation of the c-K-ras gene in human pancreatic carcinoma.

D Shibata, G Capella, M Perucho.   

Abstract

We have reported the presence of c-K-ras oncogenes activated by single point mutations at codon 12 in a vast majority of human pancreatic carcinomas. Formalin-fixed, paraffin-embedded specimens from surgical resections, autopsies and biopsies were used as well as snap frozen surgical specimens. The high oncogene incidence has been confirmed in other studies and indicate that somatic mutational activation of the c-K-ras gene is an important event in the development, maintenance or progression of cancer of the exocrine pancreas. While the role that these point mutations play in any or all of these processes remains to be determined, their presence is useful clinically for the diagnosis of pancreatic carcinoma at the molecular genetic level. The detection of mutated c-K-ras oncogenes in fine needle aspirates of pancreatic masses, that by cytomorphology may be suspicious but not diagnostic of malignant disease, increases the sensitivity of the diagnosis for this cancer. The identification of codon 12 mutations in the c-K-ras gene in pancreatic adenocarcinomas has been possible by advances in recombinant DNA techniques, especially by the development of in vitro gene amplification by the polymerase chain reaction (PCR). The possibility of analysing formalin-fixed, paraffin-embedded tissue for the presence of genetic alterations as small as single point mutations by PCR in concert with other mutation detection techniques, should facilitate the molecular genetic analysis of pancreatic carcinoma. Retrospective studies using stored specimens are now feasible with the technology described and should yield important information on the molecular epidemiology and aetiology of this and other diseases.

Entities:  

Mesh:

Year:  1990        PMID: 1976394     DOI: 10.1016/0950-3528(90)90044-h

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


  17 in total

1.  Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM).

Authors:  Asfar Sohail Azmi; Aamir Ahmad; Sanjeev Banerjee; Vivek M Rangnekar; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Pharm Res       Date:  2008-04-22       Impact factor: 4.200

Review 2.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

3.  Diagnostic value of combining CA 19-9 and K-ras gene mutation in pancreatic carcinoma: a meta-analysis.

Authors:  Jiangning Gu; Di Wang; Ya Huang; Yi Lu; Chenghong Peng
Journal:  Int J Clin Exp Med       Date:  2014-10-15

4.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

5.  Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas.

Authors:  Fatma Silan; Yener Gultekin; Sinem Atik; Davran Kilinc; Cabir Alan; Fazilet Yildiz; Ahmet Uludag; Ozturk Ozdemir
Journal:  Mol Biol Rep       Date:  2011-05-24       Impact factor: 2.316

6.  K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines.

Authors:  N Erill; M Cuatrecasas; F J Sancho; A Farré; P M Pour; F Lluís; G Capellá
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

7.  Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues.

Authors:  Ronald van Eijk; Marjo van Puijenbroek; Amiet R Chhatta; Nisha Gupta; Rolf H A M Vossen; Esther H Lips; Anne-Marie Cleton-Jansen; Hans Morreau; Tom van Wezel
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

Review 8.  Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients.

Authors:  Kristen M Drescher; Poonam Sharma; Henry T Lynch
Journal:  Clin Dev Immunol       Date:  2010-06-10

9.  Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.

Authors:  Dustin M Walters; James M Lindberg; Sara J Adair; Timothy E Newhook; Catharine R Cowan; Jayme B Stokes; Cheryl A Borgman; Edward B Stelow; Bryce T Lowrey; Maria E Chopivsky; Tona M Gilmer; John T Parsons; Todd W Bauer
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

10.  Pancreatic carcinomas of acinar and mixed acinar/ductal phenotypes in Ela-1-myc transgenic mice do not contain c-K-ras mutations.

Authors:  B K Schaeffer; P G Terhune; D S Longnecker
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.